Recent studies have focused on the intersection of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and DA signaling. While GLP agonists are widely employed for addressing type 2 diabetes, their emerging consequences on motivation circuits, specificall